Tazarotene-13C6

Tazarotene-13C6 (AGN 190168-13C6) is 13C labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

Product Name Alternative

AGN 190168-13C6

UNSPSC

12352005

Target

Autophagy; Isotope-Labeled Compounds; RAR/RXR

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=C(C1=CN=C(C=C1)C#C[13C]2=[13C][13C]=[13C]3SCCC(C)(C)[13C]3=[13C]2)OCC

Molecular Formula

C15 13C6H18NO2S

Molecular Weight

354.39

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Nagpal S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acidreceptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996 Dec;7 (12) :1783-91.|[3]Talpur R, et al. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb;5 (2) :195-210.|[4]Tang-Liu DD, et al. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999 Oct;37 (4) :273-87.